Abstract
Natural killer cells play a major role in innate immunity against tumor and virus-infected cells. NK cells express activating and inhibitory receptors to regulate their function. It has been established that modulation in the NK cell receptor profile results in altered function of NK cell against target cells. Here, we study the effect of IL-2 stimulation on NK cell inhibitory receptors Ly49A, Ly49C, and activating receptor Ly49D in C57BL/6 mice. It was observed that there was significant increase in expression of Ly49A but no change in expression of Ly49C and Ly49D on IL-2 stimulation. We further noticed that although IL-2 stimulation increased the NK cell population and expression of activation marker NK1.1 but IL-2 stimulation does not cause hyper-responsiveness in NK cells, as there was no increase in MIP-1α and IFN-γ production in IL-2 stimulated NK cells as compared to unstimulated controls. These findings provide a framework to understand the effect of IL-2 stimulation on cognate and non-cognate receptor ligand interactions and suggest stratagies for immunotherapies in conjunction with IL-2 combinatorial therapies.
Similar content being viewed by others
References
Duck Cho MD, Dario Campana MD. Expansion and activation of natural killer cells for cancer immunotherapy. Korean J Lab Med. 2009;29(2):89–96.
Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am. 2000:6(1):S11–4.
Boyman O, Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol. 2012;12(3):180–90. https://doi.org/10.1038/nri3156.
Sim GC, Radvanyi L. The IL-2 cytokine family in cancer immunotherapy. Cytokine Growth Factor Rev. 2014;25(4):377–90. https://doi.org/10.1016/j.cytogfr.2014.07.018.
Ohtani H, Mori-Shiraishi K, Nakajima M, Ueki H. Defining lymphocyte-predominant breast cancer by the proportion of lymphocyte-rich stroma and its significance in routine histopathological diagnosis. Pathol Int. 2015;65(12):644–51. https://doi.org/10.1111/pin.12355.
Dushyanthen S, Beavis PA, Savas P, Teo ZL, Zhou C, Mansour M, et al. Relevance of tumor-infiltrating lymphocytes in breast cancer. BMC Med. 2015;13(1):202. https://doi.org/10.1186/s12916-015-0431-3.
Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, et al. Durable complete responses in heavily pretreated patients with metastaticmelanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011;17(13):4550–7. https://doi.org/10.1158/1078-0432.CCR-11-0116.
Hwang WT, Adams SF, Tahirovic E, Hagemann IS, Coukos G. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol Oncol. 2012;124(2):192–8. https://doi.org/10.1016/j.ygyno.2011.09.039.
Stevanovic S, Draper LM, Langhan MM, Campbell TE, Kwong ML, Wunderlich JR, et al. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J Clin Oncol 2015:33(14):1543–50.
Schleypen JS, Baur N, Kammerer R, Nelson PJ, Rohrmann K, Grone EF, et al. CytotoxicMarkers and frequency predict functional capacity of natural killer cells infiltrating renal cell carcinoma. Clin Cancer Res. 2006;12(3):718–25. https://doi.org/10.1158/1078-0432.CCR-05-0857.
Basse PH, Goldfarb RH, Herberman RB, Hokland ME. Accumulation of adoptively transferred ANK cells in murine metastases: kinetics and role of interleukin-2. In Vivo Athens Greece 1994;8(1):17–24.
Yang Q, Hokland ME, Bryant JL, Zhang Y, Nannmark U, Watkins SC, et al. Tumor-localization by adoptively transferred, interleukin-2-activated NK cells leads to destruction of well-established lung metastases. Int J Cancer. 2003;105(4):512–9. https://doi.org/10.1002/ijc.11119.
Sarkar S, Germeraad WT, Rouschop KM, Steeghs EM, Van Gelder M, Bos GM, et al. Hypoxia induced impairment of NK cell cytotoxicity against multiple myeloma can be overcome by IL-2 activation of the NK cells. PLoS One. 2013;8(5):e64835. https://doi.org/10.1371/journal.pone.0064835.
Moon EK, Wang LC, Dolfi DV, Wilson CB, Ranganathan R, Sun J, et al. Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors. Clin Cancer Res. 2014;20(16):4262–73. https://doi.org/10.1158/1078-0432.CCR-13-2627.
Navarro AG, Björklund AT, Chekenya M. Therapeutic potential and challenges of natural killer cells in treatment of solid tumors. Front Immunol. 2015;6:202.
Kunert A, Straetemans T, Govers C, Lamers C, Mathijssen R, Sleijfer S, et al. TCR-engineered T cells meet new challenges to treat solid tumors: choice of antigen, T cell fitness, and sensitization of tumor milieu. Front Immunol. 2013;4:363.
Tahtinen S, Kaikkonen S, Merisalo-Soikkeli M, Grönberg-Vaha-Koskela S, Kanerva A, Parviainen S, et al. Favorable alteration of tumor microenvironment by immunomodulatory cytokines for efficient T-cell therapy in solid tumors. PLoS One. 2015;10(6):e0131242. https://doi.org/10.1371/journal.pone.0131242.
Schleypen JS, Von Geldern M, Weiss EH, Kotzias N, Rohrmann K, Schendel DJ, et al. Renal cell carcinoma-infiltrating natural killer cells express differential repertoires of activating and inhibitory receptors and are inhibited by specific HLA class I allotypes. Int J Cancer. 2003;106(6):905–12. https://doi.org/10.1002/ijc.11321.
Bottino C, Castriconi R, Pende D, Rivera P, Nanni M, Carnemolla B, et al. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med. 2003;198(4):557–67. https://doi.org/10.1084/jem.20030788.
Poggi A, Zocchi MRNK. Cell autoreactivity and autoimmune diseases. Front Immunol. 2014;5:27.
Schleinitz N, Vely F, Harle J-R, Vivier E. Natural killer cells in human autoimmune diseases. Immunology. 2010;131(4):451–8. https://doi.org/10.1111/j.1365-2567.2010.03360.x.
Fogel LA, Yokoyama WM, French AR. Natural killer cells in human autoimmune disorders. Arthritis Res Ther. 2013;15(4):216. https://doi.org/10.1186/ar4232.
Akesson C, Uvebrant K, Oderup C, Lynch K, Harris RA, Lernmark A, et al. Altered natural killer (NK) cell frequency and phenotype in latent autoimmune diabetes in adults (LADA) prior to insulin deficiency. Clin Exp Immunol. 2010;161(1):48–56. https://doi.org/10.1111/j.1365-2249.2010.04114.x.
Zhang Y, Wang H, Lou X, Qu X, Gao L, Liu X, et al. Decreased percentage of NKG2D+NK cells in patients with incident onset of type 1 diabetes. Clin Exp Pharmacol Physiol. 2017;44(2):180–90. https://doi.org/10.1111/1440-1681.12699.
Nabekura T, Lanier LL. Activating receptors for self-MHC class I enhance effector functions and memory differentiation of NK cells during mouse cytomegalovirus infection. Immunity. 2016;45(1):74–82. https://doi.org/10.1016/j.immuni.2016.06.024.
Reichlin A, Yokoyama WM. Natural killer cell proliferation induced by anti-NK1.1 and IL-2. Immunol Cell Biol. 1998;76(2):143–52. https://doi.org/10.1046/j.1440-1711.1998.00726.x.
Kritikou JS, Dahlberg CI, Baptista MA, Wagner AK, Banerjee PP, Gwalani LA, et al. IL-2 in the tumor microenvironment is necessary for Wiskott-Aldrich syndrome protein deficient NK cells to respond to tumors in vivo. Sci Rep. 2016;6:30636.
Pauza M, Smith KM, Neal H, Reilly C, Lanier LL, Lo D. Transgenic expression of Ly-49A in thymocytes alters repertoire selection. J Immunol. 2000;164(2):884–92. https://doi.org/10.4049/jimmunol.164.2.884.
Hanke T, Raulet DH. Cumulative inhibition of NK cells and T cells resulting from engagement of multiple inhibitory Ly49 receptors. J Immunol. 2001;166(5):3002–7. https://doi.org/10.4049/jimmunol.166.5.3002.
Acknowledgements
We thank Dr. A.N Bhatt, Institute of Nuclear Medicine and Allied Sciences for providing us the mice model and instrument facility. Authors are thankful to DST-SERB for providing financial support for the present study. Authors would like to acknowledge DTU for providing research fellowship to Richa Sharma and also providing infrastructure facilities.
All experiments involving animals were performed in Institute of Nuclear Medicine and Allied Sciences. All procedures performed in studies involving animals were in accordance with the ethical standards of the institution or practice at which the studies were conducted.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.